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Improving the quality of machine learning in 
health applications and clinical research
For machine learning developers, the use of prediction tools in real-world clinical settings can be a distant goal. 
Recently published guidelines for reporting clinical research that involves machine learning will help connect 
clinical and computer science communities, and realize the full potential of machine learning tools.
Bilal A. Mateen, James Liley, Alastair K. Denniston, Chris C. Holmes and Sebastian J. Vollmer
In the past decade, many impressive results have been reported for machine learning (ML) tools that are developed 
to assist in clinical decision making. 
However, translating these largely theoretical 
achievements to realistic settings remains 
a formidable challenge and requires active 
collaboration between ML researchers 
and healthcare experts. An important 
step towards facilitating this process is the 
extension of reporting guidelines in clinical 
and health sciences to incorporate ML and 
artificial intelligence (AI) approaches1. 
Recent examples are the SPIRIT-AI2 and 
CONSORT-AI3 checklists for reporting of 
clinical trials that involve AI methods, based 
on the original SPIRIT and CONSORT 
guidelines and drawing on pre-existing 
initiatives to support transparent reporting 
of ML model developments such as the 
TRIPOD4 guidelines. Most recently  
there has been a focus on developing an 
extension for the reporting of diagnostic 
tests involving AI1 — immediately relevant 
for clinical practice as seen in the current 
pandemic. While such checklists may  
appear cumbersome or restrictive, we argue 
in this Comment that they are essential  
to make full use of the promise of ML 
methods in healthcare and to facilitate 
eventual real-world applications. We  
invite the ML community to take an  
active role in the ongoing development  
of these guidelines.
Increasing value and reducing waste  
in ML research
Machine learning in healthcare (MLH) 
generally aims to predict some clinical 
outcome on the basis of multiple predictors. 
The potential of MLH is vast, with 
demonstrations of ML-based tools being 
able to achieve human-level or above 
diagnostic and prognostic capabilities 
having been described in almost every 
clinical specialty5. However, the number of 
ML tools adopted in clinical applications 
reflects only a fraction of the investment into 
the field as a whole, suggesting that most 
applications of MLH have not progressed 
beyond the initial publication6. On closer 
examination, there appears to be a tendency 
for ML researchers to stop once adequately 
accurate prediction (and hence novelty) 
has been demonstrated6 with translation 
into the clinical practice left to interested 
domain experts7. This translation is difficult, 
with a high failure rate6,8, but some of 
the potential difficulties may be readily 
addressable. Below we explore how the use 
of clinical reporting guidelines (and research 
frameworks more generally) can facilitate 
better translation and more clinically useful 
applications of MLH.
The role of reporting guidelines
One contributor to the complexity of 
translational research in MLH is ambiguous 
and incomplete reporting9. This issue 
is neither new nor intractable, but in 
the absence of complete information, it 
is difficult for end-users to objectively 
assess the strengths and weaknesses of any 
potential tool. This has been typified by 
reporting of predictive models during the 
COVID-19 pandemic: a recent systematic 
review10 found that among the over 100 
published prediction models for COVID-19  
risk, all had shortcomings in reporting 
that precluded assessment of their clinical 
suitability. Paired demonstrations from 
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Fig. 1 | Development cycle of ML/AI solutions for clinical care. This figure is reproduced from a piece 
describing 20 questions that should be asked prior to initiating an MLH project19. It summarizes the 
stages relevant for and affected by ML methods and their adoption in clinical care. For most projects 
this process will not be directly from start to finish, rather requiring a continuous feedback loop between 
the different stakeholders responsible for the various tasks. The purpose of the illustration is to show 
the high-level steps between getting access to data, providing examinable proof that an algorithm 
indeed accomplishes the stated goals, and translating the tool into clinical practice. Note that the 
implementation of any new algorithm is likely to influence the data routinely collected, by assigning 
increased importance in those features that are used as model inputs, while generating new information 
(that is, the model outcomes), thus completing the development cycle, and initiating a new cycle.
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subsequent validation studies have found 
simple bedside measurements outperform 
many of these models11. It is likely that 
at least some research waste could be 
avoided by full and transparent reporting, 
which helps to avoid pursuing predictive 
models that are unlikely to reach clinical 
use. It seems reasonable to expect that as a 
minimum standard, model reporting should 
include an unambiguous description of the 
entire statistical modelling pipeline, with the 
details of cohort derivation, pre-processing 
procedures (for example, missing data 
handling) and model building. Notably, 
many of the reporting-specific issues 
originally noted in the non-ML literature 
continue to be identified in more recent 
MLH studies12,13, suggesting that this is an 
issue that the community as a whole needs 
to address.
As well as potentially helping to avoid 
wasteful research, reporting guidelines serve 
an important purpose in clinical translation 
of research by identifying common elements 
of the research content that are necessary 
for verification of the method (usually 
mathematical details, model choices, and 
any new statistical methods), and those 
needed for reproducibility (generally data 
processing and analysis pipelines)2–4. Implicit 
in the requirement of reproducibility is a 
minimum expected standard for the model 
development pipeline and ongoing research. 
Although the literature on methodological 
best practices in prediction model building 
is vast, complicated even for those well 
versed in the underlying mathematical 
processes, and at times contradictory, the 
TRIPOD and forthcoming TRIPOD-ML 
guidelines provide a broad outline of 
reporting elements necessary (though not 
sufficient) for translatable MLH14. Outside 
of MLH, there is evidence to suggest that 
the introduction of reporting standards has 
generally led to improved confidence in 
study findings and enabled better decisions 
regarding interventions under evaluation15.
No success without an appreciation  
of context
A second issue is the absence of a clear 
pathway to translation, one in which 
MLH advances can be efficiently and 
effectively evaluated to the point where 
clinicians, regulators and policymakers 
can be confident that they are ready for 
safe deployment into real-world health 
contexts. Extending a predictive model to a 
clinical setting is much more complex than 
developing a predictor in a reductionist 
research context. Examples of issues 
that need to be considered are how the 
MLH output — the prediction — will be 
integrated with other clinical information, 
and how it will be presented (for example, 
as a measure of probability or a direct 
translation into recommendations on 
selecting treatments). Addressing such issues 
is fundamentally necessary for the research 
to contribute to medical practice or at least 
to proceed to clinical trials. This requires 
researchers and end-users to work together 
to build a shared understanding within each 
community of the priorities and limitations 
of the other, thereby improving the ability 
to create ML solutions that make real-world 
impact. The important function of clinical 
ML frameworks is therefore to identify core 
issues of design and delivery that would be 
considered important for a high-quality 
study that is supporting the development of 
a clinical application16.
For MLH developers, the potential 
use of a tool in a clinical context can be a 
distant goal, which is likely to contribute 
to the disconnect between the formulation 
of a prediction task and its corresponding 
clinical workflow. One way in which 
this often manifests is that without an 
awareness of the clinical context of the 
prediction task, it cannot be guaranteed 
that the experimental setting has a clinical 
homologue, in which case the research may 
be wasted. For example, there are many 
examples of computer-vision-based tools 
that seek to diagnose a single pathological 
entity in a radiograph5. However, 
radiologists are rarely interested solely in the 
diagnosis of a single pre-specified pathology 
in the image they are presented with. The 
technical contributions of developing a 
novel computer-vision-based approach 
or tool for diagnosing a single pathology 
are not wasteful but may be judged as 
such by clinicians due to lack of explicit 
accounting of how the research maps to the 
development cycle (Fig. 1). In general, while 
theoretical and technical contributions using 
clinical data to illustrate applicability are 
fundamental to the progress of the field, they 
are by nature different to attempts to create a 
prediction model for clinical practice.
using the ends to justify the means
The purpose of research is not publication, 
but rather to improve the way in which 
systems and societies function. Research 
in MLH tends to focus on theoretical 
novelty and on improved methodological 
performance on benchmark datasets17,18, 
which, while important, may be to the 
detriment of focus on application of 
methods. Indeed, we fundamentally lack 
case studies that demonstrate how the 
prospective use of MLH can substantially 
improve patient care. However, recent 
developments in the MLH literature may 
help address this issue. For example, 
the recent updates to the guidelines 
for randomized control trials and the 
development of diagnostic tools to explicitly 
address the nuances introduced by ML are 
in effect a checklist for developers1,2; they 
provide a roadmap of the expectations 
of any tool that may eventually make it 
into routine clinical practice, and hence 
are a valuable resource when designing a 
prediction modelling workflow. However, 
it is important to recognize that even for 
successfully translated work, reporting may 
fall short of the emerging ML reporting 
guidelines. These reporting guidelines 
are not benchmarks to retrospectively 
criticize such studies, but rather tools to 
provide a framework for study design, 
delivery and reporting to ensure that the 
medical community can derive the greatest 
value possible. Admittedly, in discussing 
the relevance of these tools to the ML 
community, we note that the uptake of the 
original versions of these frameworks in 
the MLH community has been low, which 
prompted the more recent AI-specific 
updates14. These updated guidelines should 
be seen as a starting point. Our hope is that 
by enfranchising the ML community and 
creating tools that are more suitable for 
ML-based interventions, groups will develop 
a sense of ownership of these frameworks, 
and thus the development of future 
iterations will serve as an opportunity for 
the MLH community, clinicians, patients, 
trialists, regulators and other stakeholders  
to work together to continue to develop  
and iterate these frameworks to be fit  
for purpose.
conclusion
Culture change is difficult, but for ML as 
a field to have the impact that we believe 
is achievable, we must transition away 
from siloed working. MLH cannot exist 
separately in the clinical and mathematical 
communities if we are to realize its full 
potential. Reporting guidelines and MLH 
frameworks represent a key step in bridging 
these two (often) separate worlds. ❐
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